22nd German Biotech Guide now also digital!
The digital version of the 22nd Guide to German Biotech Companies is now available via the free BIOCOM App! Available for smartphone and tablet users via Apple App Store and Android Store.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2151 entries already.
Entries by Thomas Gabrielczyk
How stress brings cancer to life again
Stress hormones such as cortisol or norephidrine can reawaken dormant tumour cells, a research team led by AstraZeneca has found out.
UK approves Biontech/Pfizer Covid-19 vaccine (copy 1)
Biontech and Pfizer have received emergency approval for their COVID-19 vaccine in the UK. Mass immunization could start next week, the first in Western countries.
UK approves Biontech/Pfizer Covid-19 vaccine
Biontech and Pfizer have received emergency approval for their COVID-19 vaccine in the UK. Mass immunization could start next week, the first in Western countries.
Swiss Noema Pharma raises CHF54m in Series A financing
Noema Pharma AG kicks off with CHF54m and licenced drug candidates from Roche AG.
Germany first EU country to launch COVID-19 therapy offensive?
After months of lobbying by the BIOM biotech cluster, Bavaria is launching a €50m initiative to push the best and fastest COVID-19 therapies.
Moderna to file for EU approval of mRNA-1273 vaccine
COVID-19 mRNA vaccine developer Moderna Inc reported it will file for FDA and EMA authorisation of mRNA-1273 based on Phase III results.
Drug set to rescue COVID-19 patients at ICUs
Aviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients.
Rapid antibody development to cure COVID-19
In addition to vaccination programmes, the SARS-CoV-2 pandemic requires safe and efficient treatment options for patients infected and suffering from Covid-19 disease. Virus-neutralising antibody therapeutics can not only cure COVID-19 but also protect from infection. New fast-track antibody drug programmes have achieved unprecedented timelines from discovery to the clinics and give hope to save lives and cure COVID-19.
Polyphor AG bags funding for murepavadin
Polyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.